KR101881791B1 - 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 - Google Patents
비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 Download PDFInfo
- Publication number
- KR101881791B1 KR101881791B1 KR1020187004780A KR20187004780A KR101881791B1 KR 101881791 B1 KR101881791 B1 KR 101881791B1 KR 1020187004780 A KR1020187004780 A KR 1020187004780A KR 20187004780 A KR20187004780 A KR 20187004780A KR 101881791 B1 KR101881791 B1 KR 101881791B1
- Authority
- KR
- South Korea
- Prior art keywords
- compositions
- methods
- dexmedetomidine transdermal
- withdrawal syndromes
- treating withdrawal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 title 1
- 206010048010 Withdrawal syndrome Diseases 0.000 title 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 title 1
- 229960004253 dexmedetomidine Drugs 0.000 title 1
- 239000000932 sedative agent Substances 0.000 title 1
- 230000001624 sedative effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887871P | 2013-10-07 | 2013-10-07 | |
| US61/887,871 | 2013-10-07 | ||
| PCT/US2014/059058 WO2015054063A1 (en) | 2013-10-07 | 2014-10-03 | Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167010340A Division KR20160055934A (ko) | 2013-10-07 | 2014-10-03 | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180021902A KR20180021902A (ko) | 2018-03-05 |
| KR101881791B1 true KR101881791B1 (ko) | 2018-07-25 |
Family
ID=52777130
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167010340A KR20160055934A (ko) | 2013-10-07 | 2014-10-03 | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 |
| KR1020187004780A KR101881791B1 (ko) | 2013-10-07 | 2014-10-03 | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167010340A KR20160055934A (ko) | 2013-10-07 | 2014-10-03 | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150098983A1 (ko) |
| EP (1) | EP3054934B1 (ko) |
| JP (1) | JP6231670B2 (ko) |
| KR (2) | KR20160055934A (ko) |
| CN (1) | CN105682650B (ko) |
| CA (1) | CA2924190C (ko) |
| FI (1) | FI3054934T3 (ko) |
| RU (1) | RU2648817C2 (ko) |
| TW (1) | TWI624278B (ko) |
| WO (1) | WO2015054063A1 (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101831290B1 (ko) * | 2013-10-07 | 2018-02-22 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물 |
| GB201600918D0 (en) * | 2016-01-18 | 2016-03-02 | Buzzz Pharmaceuticals Ltd | Transdermal patch |
| KR20190060007A (ko) * | 2016-10-31 | 2019-05-31 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법 |
| EP4371554A3 (en) | 2016-12-31 | 2024-08-07 | BioXcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
| CN111447927A (zh) * | 2017-12-08 | 2020-07-24 | 帝国制药美国公司 | 纳洛酮经皮给药装置及其使用方法 |
| SG11202012772XA (en) | 2018-06-27 | 2021-01-28 | Bioxcel Therapeutics Inc | Film formulations containing dexmedetomidine and methods of producing them |
| US20210267944A1 (en) | 2018-06-27 | 2021-09-02 | Bioxcel Therapeutics, Inc. | Methods for treating agitation using dexmedetomidine hydrochloride |
| CA3077561A1 (en) * | 2018-10-15 | 2020-04-15 | Amnon VARDI | Slow release cannabinoids and products thereof |
| WO2020084065A1 (en) * | 2018-10-24 | 2020-04-30 | Saniona A/S | Transdermal tropane compositions and methods for using the same |
| CA3135552C (en) * | 2019-04-17 | 2023-09-26 | Lts Lohmann Therapie-Systeme Ag | Ketamine containing transdermal therapeutic system comprising free hydroxyl groups |
| WO2021016112A2 (en) | 2019-07-19 | 2021-01-28 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
| JP2023545372A (ja) * | 2020-10-08 | 2023-10-30 | バイオエクセル セラピューティクス，インコーポレイテッド | デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 |
| US20220226288A1 (en) * | 2021-01-04 | 2022-07-21 | Bioxcel Therapeutics, Inc. | Dexmedetomidine treatment regimens |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5217718A (en) * | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
| UA48973C2 (uk) * | 1995-06-07 | 2002-09-16 | Орто-Макнейл Фармасьютікалз Інк. | Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції |
| GB9521680D0 (en) * | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
| US5891868A (en) * | 1997-11-21 | 1999-04-06 | Kaiser Foundation Health Plan, Inc. | Methods for treating postmenopausal women using ultra-low doses of estrogen |
| CZ20011188A3 (cs) * | 1998-10-02 | 2001-08-15 | 3M Innovative Properties Company | Prostředky pro slizniční podání léčiv a jejich použití u zvířat |
| US20030170195A1 (en) * | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
| JP4694967B2 (ja) * | 2003-07-31 | 2011-06-08 | 久光製薬株式会社 | 貼付剤 |
| ATE545412T1 (de) * | 2006-09-11 | 2012-03-15 | Sekisui Chemical Co Ltd | Klebende zubereitung mit desglymidodrin |
| EP2286814B1 (en) * | 2008-05-15 | 2013-10-16 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal preparation containing palonosetron |
| NZ703808A (en) * | 2010-01-08 | 2016-01-29 | Recro Pharma Inc | Topical transdermal dexmedetomidine compositions and methods of use thereof |
| DK2640389T3 (en) * | 2010-11-17 | 2015-03-09 | Hexal Ag | Transdermal therapeutic system comprising buprenorphine |
| WO2013072763A2 (en) * | 2011-11-16 | 2013-05-23 | Nometics Inc. | Non-sensitizing transdermal clonidine patch |
| SG11201403094TA (en) * | 2011-12-11 | 2014-10-30 | Recro Pharma Inc | Intranasal dexmedetomidine compositions and methods of use thereof |
| US8242158B1 (en) * | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
| EP2809307B1 (en) * | 2012-01-31 | 2017-12-20 | Grünenthal GmbH | Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine |
-
2014
- 2014-10-03 FI FIEP14852359.0T patent/FI3054934T3/fi active
- 2014-10-03 CN CN201480058703.8A patent/CN105682650B/zh active Active
- 2014-10-03 WO PCT/US2014/059058 patent/WO2015054063A1/en active Application Filing
- 2014-10-03 CA CA2924190A patent/CA2924190C/en active Active
- 2014-10-03 TW TW103134526A patent/TWI624278B/zh active
- 2014-10-03 EP EP14852359.0A patent/EP3054934B1/en active Active
- 2014-10-03 KR KR1020167010340A patent/KR20160055934A/ko active Application Filing
- 2014-10-03 JP JP2016520591A patent/JP6231670B2/ja active Active
- 2014-10-03 US US14/505,943 patent/US20150098983A1/en not_active Abandoned
- 2014-10-03 RU RU2016109632A patent/RU2648817C2/ru active
- 2014-10-03 KR KR1020187004780A patent/KR101881791B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN105682650A (zh) | 2016-06-15 |
| BR112016006200A2 (pt) | 2017-08-01 |
| WO2015054063A1 (en) | 2015-04-16 |
| CA2924190A1 (en) | 2015-04-16 |
| JP2016532643A (ja) | 2016-10-20 |
| RU2016109632A (ru) | 2017-11-15 |
| FI3054934T3 (fi) | 2024-07-19 |
| RU2648817C2 (ru) | 2018-03-28 |
| CA2924190C (en) | 2019-07-09 |
| CN105682650B (zh) | 2020-09-25 |
| KR20160055934A (ko) | 2016-05-18 |
| US20150098983A1 (en) | 2015-04-09 |
| JP6231670B2 (ja) | 2017-11-15 |
| EP3054934A4 (en) | 2017-04-05 |
| TWI624278B (zh) | 2018-05-21 |
| EP3054934A1 (en) | 2016-08-17 |
| EP3054934B1 (en) | 2024-05-22 |
| TW201521799A (zh) | 2015-06-16 |
| KR20180021902A (ko) | 2018-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101881791B1 (ko) | 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물 | |
| EP3080143A4 (en) | Methods and compositions for treating hemophilia | |
| EP3054940A4 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| EP3060207A4 (en) | Methods and compositions for treating cancer | |
| EP3054932A4 (en) | Dexmedetomidine transdermal delivery devices and methods for using the same | |
| EP3007695A4 (en) | Compositions and methods for treating anemia | |
| EP3033427A4 (en) | Compositions and methods for controlling pain | |
| HK1217650A1 (zh) | 用於治療劇痛的組合物及方法 | |
| EP2950884A4 (en) | COMPOSITIONS AND METHOD FOR TREATING SURFACES | |
| EP3052510A4 (en) | Methods and compositions for treating and/or preventing mucositis | |
| EP3054931A4 (en) | Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions | |
| EP2830654B8 (en) | Methods and compositions for treating inflammation | |
| EP3077823A4 (en) | Compositions and methods for identifying and treating cachexia or pre-cachexia | |
| EP3033081A4 (en) | Compositions and methods for treating chronic urticaria | |
| EP3077049A4 (en) | Compositions and methods for treating vitiligo | |
| EP3066472A4 (en) | Compositions and methods for detecting and/or treating inflammation | |
| EP3054930A4 (en) | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine | |
| EP3065829A4 (en) | Compositions and methods for treating melanoma | |
| EP3065550A4 (en) | Methods and compositions for treating sepsis | |
| EP3052102A4 (en) | Compositions and methods for treating cancers | |
| HK1219229A1 (zh) | 用於疼痛緩解而不致麻木的組合物和方法 | |
| EP3074022A4 (en) | Compositions and methods for inhibiting intercellular interactions | |
| EP3004395A4 (en) | Compositions and methods for treating cancer | |
| EP3082859A4 (en) | Compositions and methods for treating sarcoma | |
| EP2984185A4 (en) | Methods and compositions for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |